Reply to a fibrinolysis-first strategy for ST-elevation myocardial infarction in the COVID-19 era.

Leng, Wen-Xiu; Yang, Yue-Jin

Leng, Wen-Xiu; Yang, Yue-Jin.

Leng WX; Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China; Geriatric Cardiology Department, Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.
Yang YJ; Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. Electronic address: yangyjfw@126.com.

Int J Cardiol ; 343: 199, 2021 11 15.

Article in English | MEDLINE | ID: covidwho-1440080

Subject(s)

COVID-19; ST Elevation Myocardial Infarction; Fibrinolysis; Fibrinolytic Agents/therapeutic use; Humans; SARS-CoV-2; ST Elevation Myocardial Infarction/drug therapy; ST Elevation Myocardial Infarction/therapy; Thrombolytic Therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: ST Elevation Myocardial Infarction / COVID-19 Limits: Humans Language: English Journal: Int J Cardiol Year: 2021 Document Type: Article Affiliation country: J.ijcard.2021.09.043

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google